Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann PJ, Pekosz A, Kawaoka Y. Uraki R, et al. Among authors: otani a. Lancet Infect Dis. 2023 Apr;23(4):402-403. doi: 10.1016/S1473-3099(23)00070-1. Epub 2023 Feb 8. Lancet Infect Dis. 2023. PMID: 36773622 Free PMC article. No abstract available.
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB.
Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Saito M, Koga M, Tsutsumi T, Yamamoto S, Otani A, Kiso M, Sakai-Tagawa Y, Ueki H, Yotsuyanagi H, Imai M, Kawaoka Y. Uraki R, et al. Among authors: otani a. Lancet Infect Dis. 2023 Jan;23(1):30-32. doi: 10.1016/S1473-3099(22)00816-7. Epub 2022 Dec 7. Lancet Infect Dis. 2023. PMID: 36495917 Free PMC article. No abstract available.
Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.
Ikeda M, Okugawa S, Kashiwabara K, Moritoyo T, Kanno Y, Jubishi D, Hashimoto H, Okamoto K, Tsushima K, Uchida Y, Mitsumura T, Igari H, Tsutsumi T, Araoka H, Yatera K, Yamamoto Y, Nakamura Y, Otani A, Yamashita M, Wakimoto Y, Shinohara T, Adachi-Katayama M, Oyabu T, Kanematsu A, Harada S, Takeshita Y, Nakano Y, Miyazaki Y, Sakao S, Saito M, Ogura S, Yamasaki K, Kawasuji H, Hataji O, Inoue JI, Seto Y, Moriya K. Ikeda M, et al. Among authors: otani a. Int J Infect Dis. 2023 Mar;128:355-363. doi: 10.1016/j.ijid.2022.12.039. Epub 2023 Jan 4. Int J Infect Dis. 2023. PMID: 36610659 Free PMC article. Clinical Trial.
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Uraki R, et al. Among authors: otani a. Lancet Infect Dis. 2023 May;23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. Epub 2023 Mar 7. Lancet Infect Dis. 2023. PMID: 36898405 Free PMC article. No abstract available.
Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Theiler J, Yotsuyanagi H, Suzuki Y, Korber B, Kawaoka Y. Uraki R, et al. Among authors: otani a. Lancet Reg Health West Pac. 2023 May;34:100777. doi: 10.1016/j.lanwpc.2023.100777. Epub 2023 May 11. Lancet Reg Health West Pac. 2023. PMID: 37193320 Free PMC article. No abstract available.
Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Fukushi S, Watanabe S, Suzuki T, Kikuchi T, Yotsuyanagi H, Maeda K, Kawaoka Y. Uraki R, et al. Among authors: otani a. iScience. 2023 Oct 4;26(11):108147. doi: 10.1016/j.isci.2023.108147. eCollection 2023 Nov 17. iScience. 2023. PMID: 37876803 Free PMC article.
205 results